AI Article Synopsis

  • Polymorphisms in intron 2 of the FGFR2 gene are linked to a higher risk of breast cancer, particularly in European and Asian populations, with previous studies identifying SNPs rs2981582 and rs7895676 as significant variants.* -
  • In a study of 766 breast cancer cases and 665 controls in Siberia, three specific SNPs (rs7895676[C], rs2981582[T], and rs3135718[G]) were found to have strong associations with breast cancer risk in the Russian population.* -
  • Despite confirming the association of FGFR2 with breast cancer risk, the analysis suggested that rs7895676 is not the main causative variant, indicating that rs

Article Abstract

Polymorphisms within intron 2 of the FGFR2 gene have been associated with increased risk of breast cancer (BC) in European and Asian populations. The study by Easton et al reported two FGFR2 SNPs, rs2981582 and rs7895676, to be among those most strongly associated with BC risk. Statistical modeling suggested that rs7895676 was the variant responsible for the association observed in the region. In this work, we studied the association between seven FGFR2 SNPs, including rs2981582 and rs7895676, and BC risk in the Russian population of 766 case and 665 control women from Siberia, Russian Federation. In our population, allelic frequencies and the magnitude of linkage disequilibrium (LD) were different from those observed in European and Asian populations. The following three SNPs were significantly associated with BC in our study: rs7895676[C] (odds ratio (OR)=1.28 (1.12-1.43), P=1.7 x 10(-3)), rs2981582[T] (OR=1.46 (1.30-1.62), P=2 x 10(-6)) and rs3135718[G] (OR=1.43 (1.27-1.58), P=6 x 10(-6)). The latter two SNPs were in strong (r(2)=0.95) LD in our sample. Maximum likelihood analysis showed that the model, including rs7895676, only explains that the association is significantly (P<0.001) worse than any of the models, including either rs2981582 or rs3135718. Thus, in addition to the confirmation of association of FGFR2 with the BC risk in this new population, our study has suggested that rs7895676 is not likely to represent the causative variant.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2987029PMC
http://dx.doi.org/10.1038/ejhg.2009.98DOI Listing

Publication Analysis

Top Keywords

association fgfr2
8
fgfr2 gene
8
risk breast
8
breast cancer
8
european asian
8
asian populations
8
fgfr2 snps
8
rs2981582 rs7895676
8
association
4
gene polymorphisms
4

Similar Publications

Overcoming luminal breast cancer (BrCa) progression remains a critical challenge for improved overall patient survival. RUNX2 has emerged as a protein related to aggressiveness in triple-negative BrCa, however its role in luminal tumors remains elusive. We have previously shown that active FGFR2 (FGFR2-CA) contributes to increased tumor growth and that RUNX2 expression was high in hormone-independent mouse mammary carcinomas.

View Article and Find Full Text PDF

Introduction: Biliary tract cancer (BTC) originates from the biliary epithelium of the small ducts within the liver (intrahepatic cholangiocarcinoma, IHCC), the main ducts of the hilum (extrahepatic cholangiocarcinoma, EHCC), or in the gallbladder (gallbladder cancer, GC). Due to presentation with nonspecific symptoms as well as absence of screening, most patients present with advanced disease and unfavorable prognosis.

Areas Covered: The ABC-02 trial established the current first-line chemotherapy with gemcitabine/platinum for advanced BTC in 2010.

View Article and Find Full Text PDF

Wool traits determine the market value of fine-wool sheep, and wool fibre-breaking elongation (fibres can be stretched or elongated before they break) is one of the important wool traits. The interaction between hair follicle stem cells (HFSCs) and dermal papilla cells (DPCs) determines hair follicle development in fine wool sheep, thereby directly influencing wool traits. A genome-wide association study based on pre-sequencing data identified FGF20, which was significantly associated with wool fibre-breaking elongation.

View Article and Find Full Text PDF

Landscape and prognostic significance of oncogene drivers in metastatic castration sensitive prostate cancer.

Transl Cancer Res

November 2024

Department of Radiation Oncology, Rutgers Cancer Institute of New Jersey, Rutgers Robert Wood Johnson Medical School, Rutgers University, New Brunswick, NJ, USA.

Background: Tumor suppressors are well known drivers of cancer invasion and metastasis in metastatic castration sensitive prostate cancer (mCSPC). However, oncogenes are also known to be altered in this state, however the frequency and prognosis of these alterations are unclear. Thus, we aimed to study the spectrum of oncogene mutations in mCSPC and study the significance of these alteration on outcomes.

View Article and Find Full Text PDF

Background: Futibatinib is the only covalent inhibitor of FGFR1-4 to gain regulatory approval in oncology. Here, we present genomic analyses of tissue biopsies and circulating tumor DNA (ctDNA) from patients with one of nearly 20 tumor types treated with futibatinib in the phase I/II FOENIX study.

Patients And Methods: Eligible patients included those with ctDNA samples collected per protocol at baseline and/or progression on futibatinib in the phase Ib portion of the study for FGF/FGFR-altered advanced solid tumors or the phase II portion of the study for FGFR2 fusion/rearrangement-positive cholangiocarcinoma.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!